Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 3/20 | 0.48 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2798839 | 0.85 | POLB (0.52) | ALDH1A1MAPTPKMPOLBKCNA3 | |
| SCHEMBL7149835 | 0.76 | POLB (0.64) | ALDH1A1MAPTPOLBHPGDLMNA | |
| SCHEMBL5041916 | 0.75 | ALDH1A1 (0.60) | ALDH1A1MAPTPKMPOLBSMN1; SMN2 | |
| SCHEMBL11999986 | 0.74 | KDM4E (0.67) | ALDH1A1MAPTPKMSMN1; SMN2HPGD | |
| SCHEMBL2793723 | 0.73 | ALDH1A1 (0.53) | ALDH1A1MAPTPKMPOLBKCNA3 | |
| SCHEMBL10673575 | 0.72 | MAPK8 (0.54) | ALDH1A1MAPTPOLBSMN1; SMN2HPGD | |
| SCHEMBL1120348 | 0.71 | MAPKAPK2 (0.42) | CYP3A4 | |
| SCHEMBL2798266 | 0.70 | ALDH1A1 (0.50) | ALDH1A1MAPTPKMPOLBKCNA3 | |
| SCHEMBL6437676 | 0.70 | MAOB (0.49) | ALDH1A1 | |
| SCHEMBL7240590 | 0.69 | POLB (0.54) | ALDH1A1MAPTPOLBCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329694-B2 | Quinoxalinones as antibacterial composition | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-12-11 | — | — | US | disclosed |
| US-20100168418-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168418-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | ROS1, NOX1, ARG1 | ALDH1A1 2925/4885MAPT 4858/4885PKM 4302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.